Results 61 to 70 of about 12,502 (244)

Levosimendan: The current situation and new prospects

Revista Portuguesa de Cardiologia, 2014
Levosimendan is a pyridazinone-dinitrile derivative with positive inotropic and vasodilatory effects that has beneficial effects on myocardial performance.In previous randomized studies levosimendan improved hemodynamics and clinical course, but its ...
Nuno Moreno, Marta Tavares-Silva, André P. Lourenço, José Oliveira-Pinto, Tiago Henriques-Coelho, Adelino F. Leite-Moreira   +5 more
doaj   +1 more source

Levosimendan in decompensated heart failure patients: efficacy in a Brazilian cohort. Results of the BELIEF study [PDF]

, 2008
FUNDAMENTO: A levosimendana é um novo agente inodilatador que aumenta a contratilidade cardíaca pela sensibilização ao Ca(2+) e induz vasodilatação por meio da ativação dos canais KATP/BKCa.
ALBUQUERQUE, Denilson, BAIMA, Jader, BARRETTO, Antonio Carlos Pereira, BOCCHI, Edimar Alcides, Grupo de Estudos de Insuficiência Cardíaca da Sociedade Brasileira de Cardiologia - Estudo BELIEF, LAGE, Silvia, MOREIRA, Maria da Consolação, RASSI, Salvador, RIBEIRO, Jorge Pinto, VILAS-BOAS, Fábio   +9 more
core   +4 more sources

Levosimendan improves cardiac function and myocardial efficiency in rats with right ventricular failure

Pulmonary Circulation, 2017
Levosimendan is an inotropic and vasodilator drug, which is known to improve cardiac function in animal models of right ventricular (RV) failure. The effects of levosimendan on oxygen consumption and myocardial efficiency in the failing RV is unknown. We
Mona S. Hansen, Asger Andersen, Lars P. Tolbod, Nils H. Hansson, Roni Nielsen, Anton Vonk-Noordegraaf, Jens Erik Nielsen-Kudsk   +6 more
doaj   +1 more source

Levosimendan and Dobutamin Attenuate LPS-Induced Inflammation in Microglia by Inhibiting the NF-κB Pathway and NLRP3 Inflammasome Activation via Nrf2/HO-1 Signalling

Biomedicines
Hypovolemic shock is a circulatory failure, due to a loss in the effective circulating blood volume, that causes tissue hypoperfusion and hypoxia.
Federica Mannino, Valentina Urzì Brancati, R. Lauro, Igor Pirrotta, M. Rottura, N. Irrera, Gian Maria Cavallini, Giovanni Pallio, Eloisa Gitto, S. Manti   +9 more
semanticscholar   +1 more source

Efficacy and safety of intermittent repeated levosimendan infusions in advanced heart failure patients: the LAICA study

ESC Heart Failure, 2021
The aim of the LAICA study was to evaluate the long‐term effectiveness and safety of intermittent levosimendan infusion in patients with advanced heart failure (AdHF).
M. García-González, A. Aldea Perona, A. Lara Padrón, J. L. Morales Rull, M. Martínez‐Sellés, M. de Mora Martin, J. López Díaz, S. Lopez Fernandez, Pilar Ortiz Oficialdegui, A. Jimenez Sosa   +9 more
semanticscholar   +1 more source

Scandinavian SSAI clinical practice guideline on choice of inotropic agent for patients with acute circulatory failure [PDF]

, 2018
BackgroundAdult critically ill patients often suffer from acute circulatory failure and those with low cardiac output may be treated with inotropic agents.
Adamopoulos, Alhashemi, Alvarez, Alvarez, Arrigo, Bergh, Brouwers, Cholley, Coletta, De Backer, De Backer, Duygu, Feneck, Follath, Gamper, Garcia-Gonzalez, Gordon, Guyatt, Guyatt, Guyatt, Guyatt, Hajjej, Hultcrantz, Iyisoy, Jammer, Jentzer, Karlsberg, Koster, Laine, Landoni, Landoni, Levin, Levin, Mahmoud, Mebazaa, Mehta, Memis, Moller, Morelli, Perner, Perner, Qaseem, Rochwerg, Samimi-Fard, Savovic, Vaitsis, Vincent, Wetterslev, Wilkman, Yilmaz, Yontar   +50 more
core   +3 more sources

The effects of levosimendan in patients undergoing transcatheter aortic valve replacement- a retrospective analysis

Frontiers in Pharmacology, 2022
Background: Aortic stenosis (AS) increases left ventricular afterload, leading to cardiac damage and heart failure (HF). Transcatheter aortic valve replacement (TAVR) is an effective therapy for AS.
Zhenyan Zhao, Zhen Meng, Zhen Meng, Guangyuan Song, Chunrong Wang, Sheng Shi, Jie Zhao, Hongliang Zhang, Moyang Wang, Guannan Niu, Zheng Zhou, Jianhui Wang, Yongjian Wu   +12 more
doaj   +1 more source

The Efficacy and Safety of Levosimendan in Patients with Advanced Heart Failure: An Updated Meta-Analysis of Randomized Controlled Trials

American Journal of Cardiovascular Drugs
Intermittent ambulatory levosimendan administration has been shown in several small randomized controlled trials to benefit patients with advanced heart failure, preventing heart failure rehospitalization and mortality. We aim to investigate the totality
A. S. Elsaeidy, M. Abuelazm, R. Ghaly, Y. Soliman, A. Amin, M. El-Gohary, S. Elshenawy, A. Seri, B. Abdelazeem, Brijesh Patel, Christopher Bianco   +10 more
semanticscholar   +1 more source

Effect of Levosimendan on Acute Decompensated Right Heart Failure in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension

Frontiers in Medicine, 2022
Aims Acute decompensated right heart failure (RHF) in chronic precapillary pulmonary hypertension is often typified by a swiftly progressive syndrome involving systemic congestion.
C. Qu, Wei Feng, Qi Zhao, Qi Liu, Xing-Zhi Luo, Gang Wang, Meng Sun, Zhibo Yao, Yufei Sun, Shenglong Hou, Chunyang Zhao, Ruoxi Zhang, X. Qu   +12 more
semanticscholar   +1 more source

Cardiorenal syndrome [PDF]

, 2015
published_or_final_versio
Pai, MCP
core   +1 more source